MX2023004538A - Compuestos y metodos para el tratamiento de trastornos oculares. - Google Patents
Compuestos y metodos para el tratamiento de trastornos oculares.Info
- Publication number
- MX2023004538A MX2023004538A MX2023004538A MX2023004538A MX2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treatment
- inflammatory
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001530 keratinolytic effect Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 229940124091 Keratolytic Drugs 0.000 abstract 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 208000010217 blepharitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000744 eyelid Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094808P | 2020-10-21 | 2020-10-21 | |
| PCT/IB2021/000708 WO2022084739A1 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004538A true MX2023004538A (es) | 2023-06-19 |
Family
ID=81290138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004538A MX2023004538A (es) | 2020-10-21 | 2021-10-20 | Compuestos y metodos para el tratamiento de trastornos oculares. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230399317A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4232034A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023546452A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230110516A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116635032A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021365530A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3196146A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL302174A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023004538A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022084739A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4087655A4 (en) | 2020-01-10 | 2024-02-21 | Azura Ophthalmics Ltd | INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY |
| WO2024100454A2 (en) * | 2022-11-11 | 2024-05-16 | Azura Ophthalmics Ltd. | Composition and methods for improving signs and symptoms of ocular disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2702984C (en) * | 2007-10-19 | 2017-04-11 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
| EP3827823A1 (en) * | 2012-12-19 | 2021-06-02 | Novartis AG | Lfa-1 inhibitor formulations |
| US9463201B2 (en) * | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| WO2017055924A2 (en) * | 2015-09-28 | 2017-04-06 | M.G. Therapeutics Ltd. | Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion |
| CA3020713A1 (en) * | 2016-04-19 | 2017-10-26 | Azura Ophthalmics Ltd. | Compositions for the treatment of hyperkeratosis disorders |
| CA3057569A1 (en) * | 2017-03-29 | 2018-10-04 | Azura Ophthalmics Ltd. | Agents for increasing meibomian gland lipid secretion |
| CN110996904A (zh) * | 2017-05-19 | 2020-04-10 | 奥古根有限公司 | 眼用组合物及使用方法 |
| US20180333357A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Nanoemulsions with anti-inflammatory activity |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| WO2019096996A1 (en) * | 2017-11-17 | 2019-05-23 | Medichem, S.A. | A process to obtain a tetrahydroisoquinoline derivative |
| WO2020212755A1 (en) * | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
-
2021
- 2021-10-20 CN CN202180086872.2A patent/CN116635032A/zh active Pending
- 2021-10-20 IL IL302174A patent/IL302174A/en unknown
- 2021-10-20 US US18/033,055 patent/US20230399317A1/en active Pending
- 2021-10-20 WO PCT/IB2021/000708 patent/WO2022084739A1/en not_active Ceased
- 2021-10-20 AU AU2021365530A patent/AU2021365530A1/en not_active Abandoned
- 2021-10-20 EP EP21882227.8A patent/EP4232034A4/en active Pending
- 2021-10-20 MX MX2023004538A patent/MX2023004538A/es unknown
- 2021-10-20 KR KR1020237016473A patent/KR20230110516A/ko active Pending
- 2021-10-20 CA CA3196146A patent/CA3196146A1/en active Pending
- 2021-10-20 JP JP2023524274A patent/JP2023546452A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4232034A1 (en) | 2023-08-30 |
| CN116635032A (zh) | 2023-08-22 |
| US20230399317A1 (en) | 2023-12-14 |
| CA3196146A1 (en) | 2022-04-28 |
| KR20230110516A (ko) | 2023-07-24 |
| IL302174A (en) | 2023-06-01 |
| AU2021365530A1 (en) | 2023-06-15 |
| AU2021365530A9 (en) | 2024-02-08 |
| JP2023546452A (ja) | 2023-11-02 |
| EP4232034A4 (en) | 2024-12-04 |
| WO2022084739A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004537A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| WO2020212760A3 (en) | Compounds and methods for the treatment of ocular disorders | |
| Aragona et al. | Modern approach to the treatment of dry eye, a complex multifactorial disease: a PICASSO board review | |
| Jassim et al. | Crosstalk between dysfunctional mitochondria and inflammation in glaucomatous neurodegeneration | |
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| MX2020003534A (es) | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. | |
| MX2023004539A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| CL2025001153A1 (es) | Agentes de arni para inhibir la expresión de la proteína quinasa dm1 (dmpk) | |
| ECSP22086300A (es) | Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas | |
| MX2021016055A (es) | Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis. | |
| AR033151A1 (es) | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares | |
| Chen et al. | Nonsteroidal anti-inflammatory drugs for retinal neurodegenerative diseases | |
| EP3416617B1 (en) | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| AR092842A1 (es) | Tratamiento de enfermedades inflamatorias oculares usando laquinimod | |
| MX2022013665A (es) | Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares. | |
| RU2020119228A (ru) | Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи | |
| RU2672564C2 (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| CL2025001428A1 (es) | Composiciones farmacéuticas para administración ocular | |
| WO2017152129A3 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
| EP4308708A4 (en) | OCULAR ADMINISTRATION OF THERAPEUTIC AGENTS | |
| WO2023067387A3 (en) | Compounds and methods for the treatment of dermal and ocular disorders | |
| MX2023012793A (es) | Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas. |